Modulation of the anticancer immunity by natural agents: inhibition of T regulatory lymphocyte generation by arabinoxylan in patients with locally limited or metastatic solid tumors PEER REVIEWED

  • P. Lissoni, G. Messina, F. Brivio, L. Fumagalli, L. Vigore, F. Rovelli, L. Maruelli, M. Miceli, P. Marchiori, G. Porro, M. Held, G. di Fede, T Uchiyamada
  • (edited by Chris Gutch PhD.)
  • 2008

In the last years, several immunomodulating antitumor agents have demonstrated in the nature, particularly from Aloe plant and rice bran. However, the major problem concerning the natural antitumor agents is to define their immune mechanisms of action in relation to the more recent advances in tumor immunobiology.

At present, the main cause responsible for the lack of an effective antitumor response in advanced cancer patients is belived to be represented by the generation of a subtype of T helper lymphocytes (CD4) with suppressive activity on anticancer immunity, the so-called T regulatory lymphocytes (T reg), which may be clinically identified as CD4*CD25* cells.

On this basis, a study was planned to evaluate the effect of rice bran extract arabinoxylan on T reg cell count and percentage in solid tumor patients in relation to the various lymphocyte subpopulations. The study included 22 evaluable cancer patients, 16 of whom had an untreatable metastatic solid tumor. Arabinoxylan was given orally at a dose of 2000 mg/day for the first month, followed by a dose of 1000 mg/day for the next month. In each patient we evaluated by monoclonal antibodies the absolute number of lymphocytes, T lymphocytes (CD3*), T helper (TH) lymphocytes (CD4*), T cytotoxic lymphocytes (CD8*), NK cells (CD16*CD56*), T reg lymphocytes (CD4*CD25*) and TH/T reg ratio before and after 2 months of therapy. No substantial change occurred on therapy in the mean number of lymphocytes, CD3*, CD8* and NK cells. On the other hand, the mean number of TH cells increased, whereas that of T reg cell decreased on treatment, even though none of these differences was statistically significant. On the contrary, TH/T reg mean ratio significantly enhanced after arabinoxylan therapy. In addition to its previously demonstrated stimulatory action on NK function, this study shows that arabinoxylan may inhibit the production of T reg cells, which are responsible for cancer-related immunosuppression, with a following improvement in the anticancer immunity.

If further studies will confirm these results, arabinoxylan could be successfully associated with chemotherapy to induce not only a cytotoxic destruction of cancer cells, but also an improvement in the immune status.

We use cookies to improve your experience on our website. For more details see our cookie policy.

Like many other websites, we use cookies to provide enhanced functionality and track the usage of our websites with Google Analytics, and some of our third-party advertisers might use them to deliver adverts tailored to what they think you might be interested in.

What are cookies?

Cookies are small text files which can be sent to browser when you visit websites and saved to your device (computer or other device with Internet access, i.e. smartphone or tablet). Cookies are saved in the folder for files of your browser. Cookies usually contain the name of the website they come from and the date of origin. Upon your next visit the browser loads cookies again and sends these information back to the website which originally created cookies. Cookies we use do not harm your computer.

Using cookies

By using this website you give your consent to using cookies in compliance with your browser settings. If you visit our websites, acceptance of cookies is allowed in your browser, you do not change your browser settings and continue visiting our websites we consider it as accepting our conditions for using cookies.

Why are we using cookies?

Cookies are used to optimally create and constantly improve the quality of our services, adjust them to your interests and needs and improve their structure and contents. We do not use data obtained by using cookies to contact users by mail, e-mail or telephone.

How to change settings of cookies?

Majority of browsers have been originally set to automatically accept cookies. This settings can be changed by blocking cookies or by a notification in case cookies are to be sent to your device. Instructions for changing cookies are available in the option “Help” of every browser. If you use different devices to access websites (e.g. computer, smartphone, tablet), we recommend you to adjust every browser on each of them to your preferences regarding cookies.

Why to keep settings of cookies?

Using cookies and permitting cookies in your browser is your decision. However, in case you change settings of cookies, functionality of some of our websites can be limited and their user comfort reduced.